TY - JOUR
T1 - English version of guidelines for the management of asteatosis 2021 in Japan
AU - Saeki, Hidehisa
AU - Tsunemi, Yuichiro
AU - Arai, Satoru
AU - Ichiyama, Susumu
AU - Katoh, Norito
AU - Kikuchi, Katsuko
AU - Kubo, Akiharu
AU - Terui, Tadashi
AU - Nakahara, Takeshi
AU - Futamura, Masaki
AU - Murota, Hiroyuki
AU - Igarashi, Atsuyuki
N1 - Funding Information:
According to the criteria for the conflict of interest at the institutions of each committee member or the “COI Management Guidelines” ( http://jams.med.or.jp/guideline/coi_guidelines_2020.pdf ) and the “Guidance on Eligibility for Participation in the Formulation of Clinical Practice Guidelines” ( http://jams.med.or.jp/guideline/clinical_guidance.pdf ) of the Japanese Association of Medical Sciences, the committee members of the present guidelines disclosed their conflicts of interest (COI) for the past 3 years until the inauguration and each year until the publication of the guidelines. The costs to develop the guidelines have been supported by grants for research from the Japanese Dermatological Association (JDA). The members of this committee have not received any rewards for the development of the guidelines or participation in related meetings. There has been no intervention by the Ministry of Health, Labor, and Welfare or the JDA that may influence the contents of the guidelines. To avoid any influence by potential COI, if any, on the guidelines, all recommendations were determined based on consensus voting, rather than on individual opinion. With respect to clinical questions (CQ) to be voted, committee members with financial, academic, or other COI beyond the regulations must abstain from voting, although they can participate in discussion. Concerning the CQ regarded as non‐specialty by each committee member, it was possible to select abstention from voting. Furthermore, the contents were polished in reference to the opinions of the representatives of the JDA (public comments).
Publisher Copyright:
© 2021 Japanese Dermatological Association
PY - 2022/3
Y1 - 2022/3
N2 - This is the English version of guidelines for the management of asteatosis 2021 in Japan. Asteatosis is a synonym of xerosis found in a wide range of diseases that induce dry skin through impaired functions of either water retention of the stratum corneum or skin covering with acid mantle. Patients with asteatosis may be accompanied by pruritus. Moisturizers are the first-line treatment for asteatosis and their adequate use must be recommended. The main purpose of the present guidelines is to define skin symptoms requiring treatment with moisturizers for medical use in patients with asteatosis. If the deterioration of marked scaling or scratch marks is predicted, therapeutic intervention with moisturizers for medical use should be considered even in the absence of pruritus. Regarding six important points requiring decision-making in clinical practice (clinical questions), we evaluated the balance between the benefits and harm of medical interventions in reference to previous reports of clinical research, and presented the recommendation grades and evidence levels to optimize the patient outcome by medical interventions.
AB - This is the English version of guidelines for the management of asteatosis 2021 in Japan. Asteatosis is a synonym of xerosis found in a wide range of diseases that induce dry skin through impaired functions of either water retention of the stratum corneum or skin covering with acid mantle. Patients with asteatosis may be accompanied by pruritus. Moisturizers are the first-line treatment for asteatosis and their adequate use must be recommended. The main purpose of the present guidelines is to define skin symptoms requiring treatment with moisturizers for medical use in patients with asteatosis. If the deterioration of marked scaling or scratch marks is predicted, therapeutic intervention with moisturizers for medical use should be considered even in the absence of pruritus. Regarding six important points requiring decision-making in clinical practice (clinical questions), we evaluated the balance between the benefits and harm of medical interventions in reference to previous reports of clinical research, and presented the recommendation grades and evidence levels to optimize the patient outcome by medical interventions.
UR - http://www.scopus.com/inward/record.url?scp=85122505124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122505124&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.16293
DO - 10.1111/1346-8138.16293
M3 - Article
C2 - 34970776
AN - SCOPUS:85122505124
SN - 0385-2407
VL - 49
SP - e77-e90
JO - Journal of Dermatology
JF - Journal of Dermatology
IS - 3
ER -